According to recent studies, the detection of CTCs in the peripheral blood of ovarian cancer patients is correlated with the tumor stage, disease recurrence, shorter OS and PFS, the presence of ascites and sub-optimal debulking as well as the elevated levels of CA125 and HE4 proteins in serum19–26. This evidence concerns the gene WFDC2 and neoplasm.